立足中国实际的原发免疫性血小板减少症诊治——2020版成人原发免疫性血小板减少症诊断与治疗中国指南解读

侯明; 刘新光

doi:10.13201/j.issn.1004-2806.2021.01.001

立足中国实际的原发免疫性血小板减少症诊治——2020版成人原发免疫性血小板减少症诊断与治疗中国指南解读

侯明^,,
刘新光

- 山东大学齐鲁医院血液科(济南, 250012)

详细信息

作者简介:
侯明,山东大学齐鲁医院肿瘤中心主任、血液科主任,山东省血液免疫重点实验室主任,泰山学者、山东大学二级教授、博士生导师。ITP国际工作组指南制定专家组成员,ASH资深会员、APSTH执委,中华医学会血液学分会常委,中国病理生理协会实验血液学会常委,中国医师协会血液科医师分会副会长。在ITP的发病机制、特异诊断及治疗方面取得一系列创新性成果,多次获得教育部自然科学奖、科学技术进步奖等重要奖励。致力于ITP的基础与临床研究,在国内外处于领先水平,为国内乃至国际ITP诊断治疗领域首屈一指的医学大家。

通讯作者: 侯明,E-mail:houming@medmail.com.cn

中图分类号: R558.2

收稿日期: 2020-10-15

Diagnosis and treatment of primary immune thrombocytopenia according to the actual situation of China:interpretation of the Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia （version 2020）

HOU Ming^,,
LIU Xinguang

More Information

Corresponding author: HOU Ming, E-mail: houming@medmail.com.cn

Received Date: 15 October 2020

摘要

摘要: 原发免疫性血小板减少症（primary immune thrombocytopenia,ITP）是临床最为常见的获得性自身免疫性出血性疾病,以缺乏明确特异病因的孤立性血小板减少为特征。随着国内外对ITP发病机制及治疗领域的不断探索,ITP的诊治受到广泛关注,成为热点领域之一。依据近年来ITP诊治领域最新循证医学证据进展,参照2019版ITP国际工作组共识报告更新及美国血液学会（ASH）ITP诊治指南更新,立足我国实际情况,充分征求血栓与止血学组专家意见,反复商讨后制定了2020版的《成人ITP诊断与治疗中国指南》^[1],旨在进一步普及ITP相关知识、澄清概念,并推动国内成人ITP的规范化诊治。在此,对新版指南修订内容进行解读,以期临床医师更好地使用该指南。
- 原发免疫性血小板减少症 /
- 诊断 /
- 治疗
- primary immune thrombocytopenia /
- diagnosis /
- management

HTML全文

参考文献(17)

[1]	中华医学会血液学分会血栓与止血学组.成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J].中华血液学杂志,2020,41(8):617-623.
[2]	Provan D,Arnold DM,Bussel JB,et al.Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood Adv,2019,3(22):3780-3817.
[3]	Kuendgen A,Matsuda A,Germing U.Differences in epidemiology of MDS between Western and Eastern countries:Ethnic differences or environmental influence?[J].Leuk Res,2007,31(1):103-104.
[4]	中华医学会血液学分会红细胞疾病(贫血)学组.再生障碍性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(1):1-5.
[5]	Wei Y,Ji XB,Wang YW,et al.High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia:a prospective multicenter randomized trial[J].Blood,2016,127(3):296-302;quiz 370.
[6]	Mithoowani S,Gregory-Miller K,Goy J,et al.High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia:a systematic review and meta-analysis[J].Lancet Haematol,2016,3(10):e489-e496.
[7]	中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中华传染病杂志,2019,37(12):711-736.
[8]	Peng J,Ma SH,Liu J,et al.Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia:a multicenter cohort study[J].J Thromb Haemost,2014,12(4):497-504.
[9]	Marangon M,Vianelli N,Palandri F,et al.Rituximab in immune thrombocytopenia:gender,age,and response as predictors of long-term response[J].Eur J Haematol,2017,98(4):371-377.
[10]	Cervinek L,Cerna O,Caniga M,et al.Efficacy of rituximab in primary immune thrombocytopenia:an analysis of adult pretreated patients from everyday hematological practice[J].Int J Hematol,2012,96(5):594-599.
[11]	Thai LH,Mahevas M,Roudot-Thoraval F,et al.Long-term complications of splenectomy in adult immune thrombocytopenia[J].Medicine(Baltimore),2016,95(48):e5098.
[12]	Boyle S,White RH,Brunson A,et al.Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia[J].Blood,2013,121(23):4782-4790.
[13]	Feng FE,Feng R,Wang M,et al.Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia:a multicentre,randomised,open-label,phase 2 trial[J].Lancet Haematol,2017,4(10):e487-e496.
[14]	Zhou H,Qin P,Liu Q,et al.A prospective,multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia[J].Am J Hematol,2019,94(12):1374-1381.
[15]	ACOG Practice Bulletin No.207 Summary:Thrombocytopenia in Pregnancy[J].Obstet Gynecol,2019,133(3):589-591.
[16]	Sun D,Shehata N,Ye XY,et al.Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy[J].Blood,2016,128(10):1329-1335.
[17]	Kong Z,Qin P,Xiao S,et al.A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy[J].Blood,2017,130(9):1097-1103.